Corcept Therapeutics Presents Positive Results From Phase 2 Trial Of Relacorilant On Ovarian Cancer

Corcept Therapeutics Inc. (CORT) said that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer were featured in a proffered paper oral presentation at the European Society for Medical Oncology Congress 2021.

The results showed statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept's proprietary selective cortisol modulator, relacorilant.

Corcept Therapeutics noted thar the results presented at ESMO today demonstrated the benefit experienced by the women who received relacorilant - delayed disease progression without increased side effect burden. The company and its investigators are excited to begin a pivotal Phase 3 trial in the first quarter of next year to confirm these results.

Women who received the higher dose of relacorilant intermittently exhibited a statistically significant improvement in median progression free survival (PFS) compared to those who received nab-paclitaxel alone.

The women in the Intermittent arm also experienced a statistically significant improvement in the duration of response (DoR) relative to those in the Comparator arm.

While the overall survival (OS) data was only 63% mature at the time of the database cut-off, the women in the Intermittent arm exhibited a median OS of 12.9 months versus 10.4 months in the Comparator arm.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT